Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.
暂无分享,去创建一个
[1] G. Denardo,et al. Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma , 2007, Journal of Nuclear Medicine.
[2] Arutselvan Natarajan,et al. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] S. Denardo,et al. Recombinant antibodies: from the laboratory to the clinic. , 2006, Cancer biotherapy & radiopharmaceuticals.
[4] Arutselvan Natarajan,et al. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. , 2006, Protein engineering, design & selection : PEDS.
[5] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[6] R. Ivkov,et al. Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy , 2005, Clinical Cancer Research.
[7] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[8] H. Honda,et al. Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. , 2005, Journal of bioscience and bioengineering.
[9] Anna Moore,et al. In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe , 2004, Cancer Research.
[10] Č. Venclovas,et al. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] Peter Bohlen,et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. , 2001, Cancer research.
[12] J. Wong,et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.
[13] K. Tsumoto,et al. Construction of a diabody (small recombinant bispecific antibody) using a refolding system. , 2000, Protein engineering.
[14] G W Beresford,et al. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. , 2000, Journal of biochemistry.
[15] K. Lamborn,et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. , 2000, Cancer biotherapy & radiopharmaceuticals.
[16] G. Landes,et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. , 1999, Cancer research.
[17] R Weissleder,et al. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. , 1999, Bioconjugate chemistry.
[18] J. Taylor‐Papadimitriou,et al. A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells. , 1998, Cancer biochemistry biophysics.
[19] S. Barratt-Boyes. Making the most of mucin: a novel target for tumor immunotherapy , 1996, Cancer Immunology, Immunotherapy.
[20] L E Williams,et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.
[21] G. Denardo,et al. Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3) , 1994, Cancer.
[22] W Wood,et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. A. Edwards. The Technique of Whole-Body Autoradiography , 1988 .
[24] J. Overgaard,et al. Effect of hyperthermia on malignant cells in vivo: A review and a hypothesis , 1977, Cancer.
[25] G. Denardo,et al. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. , 2005, Bioconjugate chemistry.
[26] Hiroyuki Honda,et al. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. , 2003, Journal of bioscience and bioengineering.
[27] Taylor Murray,et al. Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.
[28] Thomas E. Creighton,et al. Protein structure : a practical approach , 1997 .
[29] C. Streffer,et al. The biological basis for tumour therapy by hyperthermia and radiation. , 1987, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.